Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations.
Journal
Nature reviews. Endocrinology
ISSN: 1759-5037
Titre abrégé: Nat Rev Endocrinol
Pays: England
ID NLM: 101500078
Informations de publication
Date de publication:
09 Feb 2024
09 Feb 2024
Historique:
accepted:
19
12
2023
medline:
10
2
2024
pubmed:
10
2
2024
entrez:
9
2
2024
Statut:
aheadofprint
Résumé
Tumours of the anterior part of the pituitary gland represent just 1% of all childhood (aged <15 years) intracranial neoplasms, yet they can confer high morbidity and little evidence and guidance is in place for their management. Between 2014 and 2022, a multidisciplinary expert group systematically developed the first comprehensive clinical practice consensus guideline for children and young people under the age 19 years (hereafter referred to as CYP) presenting with a suspected pituitary adenoma to inform specialist care and improve health outcomes. Through robust literature searches and a Delphi consensus exercise with an international Delphi consensus panel of experts, the available scientific evidence and expert opinions were consolidated into 74 recommendations. Part 1 of this consensus guideline includes 17 pragmatic management recommendations related to clinical care, neuroimaging, visual assessment, histopathology, genetics, pituitary surgery and radiotherapy. While in many aspects the care for CYP is similar to that of adults, key differences exist, particularly in aetiology and presentation. CYP with suspected pituitary adenomas require careful clinical examination, appropriate hormonal work-up, dedicated pituitary imaging and visual assessment. Consideration should be given to the potential for syndromic disease and genetic assessment. Multidisciplinary discussion at both the local and national levels can be key for management. Surgery should be performed in specialist centres. The collection of outcome data on novel modalities of medical treatment, surgical intervention and radiotherapy is essential for optimal future treatment.
Identifiants
pubmed: 38336897
doi: 10.1038/s41574-023-00948-8
pii: 10.1038/s41574-023-00948-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Limited.
Références
Fisher, B. J., Gaspar, L. E., Stitt, L. W. & Noone, B. E. Pituitary adenoma in adolescents: a biologically more aggressive disease? Radiology 192, 869–872 (1994).
pubmed: 8058963
doi: 10.1148/radiology.192.3.8058963
Beckers, A., Petrossians, P., Hanson, J. & Daly, A. F. The causes and consequences of pituitary gigantism. Nat. Rev. Endocrinol. 14, 705–720 (2018).
pubmed: 30361628
doi: 10.1038/s41574-018-0114-1
Barry, S. & Korbonits, M. Update on the genetics of pituitary tumors. Endocrinol. Metab. Clin. North Am. 49, 433–452 (2020).
pubmed: 32741481
doi: 10.1016/j.ecl.2020.05.005
National Cancer Registration and Analysis Service. Children, Teenagers and Young Adults UK Cancer Statistics Report 2021, Public Health England http://www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/cancer_in_children_teenagers_and_young_adults/ (2021).
Kelly, A. P., Greenfield, J. P., Dobri, G. A. & Schwartz, T. H. Pediatric pituitary adenomas are more aggressive, more likely to be hormone producing and are more difficult to cure than adult pituitary adenomas: case series and systematic literature review. Childs Nerv. Syst. 38, 729–738 (2022).
pubmed: 35048170
doi: 10.1007/s00381-022-05445-3
Jayant, S. S. et al. Paediatric pituitary adenomas: clinical presentation, biochemical profile and long-term prognosis. Neurol. India 70, 304–311 (2022).
pubmed: 35263901
Asa, S. L. et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr. Relat. Cancer 24, C5–C8 (2017).
pubmed: 28264912
doi: 10.1530/ERC-17-0004
Trouillas, J. et al. Aggressive pituitary tumours and carcinomas: two sides of the same coin? Eur. J. Endocrinol. 178, C7–C9 (2018).
pubmed: 29588294
doi: 10.1530/EJE-18-0250
Ho, K. K. Y. et al. A tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement. Pituitary 22, 569–573 (2019).
pubmed: 31571098
doi: 10.1007/s11102-019-00988-2
Ho, K. K. Y. et al. The tale in evolution: clarity, consistency and consultation, not contradiction and confusion. Pituitary 23, 476–477 (2020).
pubmed: 31912348
doi: 10.1007/s11102-019-01027-w
Asa, S. L. et al. Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution. Pituitary 23, 322–325 (2020).
pubmed: 31834538
doi: 10.1007/s11102-019-01015-0
Asa, S. L., Mete, O., Perry, A. & Osamura, R. Y. Overview of the 2022 WHO classification of pituitary tumors. Endocr. Pathol. 33, 6–26 (2022).
pubmed: 35291028
doi: 10.1007/s12022-022-09703-7
Ho, K. K. Y. et al. Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification. Nat. Rev. Endocrinol. 19, 671–678 (2023).
pubmed: 37592077
doi: 10.1038/s41574-023-00883-8
Castellanos, L. E., Misra, M., Smith, T. R., Laws, E. R. & Iorgulescu, J. B. The epidemiology and management patterns of pediatric pituitary tumors in the United States. Pituitary 24, 412–419 (2021).
pubmed: 33433891
pmcid: 8415131
doi: 10.1007/s11102-020-01120-5
National Cancer Registration and Analysis Service. Cancer in children, teenagers and young adults, http://ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/cancer_in_children_teenagers_and_young_adults/ (Access date:11/04/2023).
Korbonits, M. et al. Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: part 2, specific diseases. Nat. Rev. Endocrinol. https://doi.org/10.1038/s41574-023-00949-7 (2024).
Brouwers, M. C. et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can. Med. Assoc. J. 182, E839–842 (2010).
doi: 10.1503/cmaj.090449
Children’s Cancer and Leukaemia Group. Children’s Cancer and Leukaemia Guideline Development Standard Operating Procedure, Version 5 https://www.cclg.org.uk/what-we-do/clinical-treatment-guidelines (Access date: 19/01/2022).
Schardt, C., Adams, M. B., Owens, T., Keitz, S. & Fontelo, P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med. Inform. Decis. Mak. 7, 16 (2007).
pubmed: 17573961
pmcid: 1904193
doi: 10.1186/1472-6947-7-16
Atkins, D. et al. Grading quality of evidence and strength of recommendations. BMJ 328, 1490 (2004).
pubmed: 15205295
doi: 10.1136/bmj.328.7454.1490
Perry, A. et al. Pediatric pituitary adenoma: case series, review of the literature, and a skull base treatment paradigm. J. Neurol. Surg. B Skull Base 79, 91–114 (2018).
pubmed: 29404245
pmcid: 5796823
doi: 10.1055/s-0038-1625984
Freund, K. et al. A 7-year update report of a national, interdisciplinary endeavour to improve outcomes for children and young people under 19 years of age with hypothalamic pituitary axis tumours (HPAT) using multi-site video conferencing. Horm. Res. Paediatr. 90 (Suppl. 1), 496–497 (2018).
Batista, D. et al. Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with Cushing disease. J. Clin. Endocrinol. Metab. 90, 5134–5140 (2005).
pubmed: 15941871
doi: 10.1210/jc.2004-1778
Patronas, N. et al. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J. Clin. Endocrinol. Metab. 88, 1565–1569 (2003).
pubmed: 12679440
doi: 10.1210/jc.2002-021438
Chowdhury, I. N., Sinaii, N., Oldfield, E. H., Patronas, N. & Nieman, L. K. A change in pituitary magnetic resonance imaging protocol detects ACTH-secreting tumours in patients with previously negative results. Clin. Endocrinol. 72, 502–506 (2010).
doi: 10.1111/j.1365-2265.2009.03646.x
Arbab, A. S. 3D gradient echo sequence provides better images in contrast-enhanced imaging of the pituitary gland at 3 T. Imaging Med. 2, 129–130 (2010).
pubmed: 21278809
pmcid: 3027067
doi: 10.2217/iim.10.16
Kakite, S. et al. Three-dimensional gradient echo versus spin echo sequence in contrast-enhanced imaging of the pituitary gland at 3T. Eur. J. Radiol. 79, 108–112 (2011).
pubmed: 20116954
doi: 10.1016/j.ejrad.2009.12.036
Kasaliwal, R. et al. Volume interpolated 3D-spoiled gradient echo sequence is better than dynamic contrast spin echo sequence for MRI detection of corticotropin secreting pituitary microadenomas. Clin. Endocrinol. 78, 825–830 (2013).
doi: 10.1111/cen.12069
Gan, H. W. et al. National UK guidelines for the management of paediatric craniopharyngioma. Lancet Diabetes Endocrinol. 11, 694–706 (2023).
pubmed: 37549682
doi: 10.1016/S2213-8587(23)00162-6
Cerbone, M. et al. Management of children and young people with idiopathic pituitary stalk thickening, central diabetes insipidus, or both: a national clinical practice consensus guideline. Lancet Child. Adolesc. Health 5, 662–676 (2021).
pubmed: 34214482
doi: 10.1016/S2352-4642(21)00088-2
Bashari, W. A. et al. Using molecular imaging to enhance decision making in the management of pituitary adenomas. J. Nucl. Med. 62, 57S–62S (2021).
pubmed: 34230075
doi: 10.2967/jnumed.120.251546
Veldhuijzen van Zanten, S. E. M., Neggers, S., Valkema, R. & Verburg, F. A. Positive [
pubmed: 34223953
pmcid: 8712289
doi: 10.1007/s00259-021-05458-1
Pinker, K. et al. The value of high-field MRI (3T) in the assessment of sellar lesions. Eur. J. Radiol. 54, 327–334 (2005).
pubmed: 15899332
doi: 10.1016/j.ejrad.2004.08.006
Berkmann, S., Fandino, J., Muller, B., Remonda, L. & Landolt, H. Intraoperative MRI and endocrinological outcome of transsphenoidal surgery for non-functioning pituitary adenoma. Acta Neurochir. 154, 639–647 (2012).
pubmed: 22286656
doi: 10.1007/s00701-012-1285-5
Szerlip, N. J. et al. Transsphenoidal resection of sellar tumors using high-field intraoperative magnetic resonance imaging. Skull Base 21, 223–232 (2011).
pubmed: 22470265
pmcid: 3312115
doi: 10.1055/s-0031-1277262
Nimsky, C., von Keller, B., Ganslandt, O. & Fahlbusch, R. Intraoperative high-field magnetic resonance imaging in transsphenoidal surgery of hormonally inactive pituitary macroadenomas. Neurosurgery 59, 105–114 (2006).
pubmed: 16823306
doi: 10.1227/01.neu.0000243289.98791.05
Wu, J. S. et al. Transsphenoidal pituitary macroadenomas resection guided by PoleStar N20 low-field intraoperative magnetic resonance imaging: comparison with early postoperative high-field magnetic resonance imaging. Neurosurgery 65, 63–70 (2009).
pubmed: 19574826
doi: 10.1227/01.NEU.0000348549.26832.51
Fomekong, E. et al. Intraoperative 3T MRI for pituitary macroadenoma resection: initial experience in 73 consecutive patients. Clin. Neurol. Neurosurg. 126, 143–149 (2014).
pubmed: 25255158
doi: 10.1016/j.clineuro.2014.09.001
Zhang, H. et al. Analysis of 137 patients who underwent endoscopic transsphenoidal pituitary adenoma resection under high-field intraoperative magnetic resonance imaging navigation. World Neurosurg. 104, 802–815 (2017).
pubmed: 28434959
doi: 10.1016/j.wneu.2017.04.056
Staartjes, V. E., Togni-Pogliorini, A., Stumpo, V., Serra, C. & Regli, L. Impact of intraoperative magnetic resonance imaging on gross total resection, extent of resection, and residual tumor volume in pituitary surgery: systematic review and meta-analysis. Pituitary 24, 644–656 (2021).
pubmed: 33945115
pmcid: 8270798
doi: 10.1007/s11102-021-01147-2
Holowka, S., Shroff, M. & Chavhan, G. B. Use and safety of gadolinium based contrast agents in pediatric MR imaging. Indian J. Pediatr. 86, 961–966 (2019).
pubmed: 30796704
doi: 10.1007/s12098-019-02891-x
Bonneville, J. F. A plea for the T2W MR sequence for pituitary imaging. Pituitary 22, 195–197 (2019).
pubmed: 30488370
doi: 10.1007/s11102-018-0928-9
Shah, R., D’Arco, F., Soares, B., Cooper, J. & Brierley, J. Use of gadolinium contrast agents in paediatric population: Donald Rumsfeld meets hippocrates! Br. J. Radiol. 92, 20180746 (2019).
pubmed: 30412428
doi: 10.1259/bjr.20180746
Schieda, N. et al. Gadolinium-based contrast agents in kidney disease: a comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. Can. J. Kidney Health Dis. 5, 2054358118778573 (2018).
pubmed: 29977584
pmcid: 6024496
doi: 10.1177/2054358118778573
Suharwardy, J. & Elston, J. The clinical presentation of children with tumours affecting the anterior visual pathways. Eye 11, 838–844 (1997).
pubmed: 9537141
doi: 10.1038/eye.1997.215
Drimtzias, E. et al. The ophthalmic natural history of paediatric craniopharyngioma: a long-term review. J. Neurooncol. 120, 651–656 (2014).
pubmed: 25173232
doi: 10.1007/s11060-014-1600-5
Avery, R. A., Bouffet, E., Packer, R. J. & Reginald, A. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas. Invest. Ophthalmol. Vis. Sci. 54, 1034–1038 (2013).
pubmed: 23329671
doi: 10.1167/iovs.12-11385
Avery, R. A. et al. Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J. Neurooncol. 110, 1–7 (2012).
pubmed: 22843451
doi: 10.1007/s11060-012-0944-y
Beck, R. W. et al. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology 114, 1804–1809 (2007).
pubmed: 17908590
doi: 10.1016/j.ophtha.2007.06.047
Fulton, A. B., Hansen, R., Moskowitz, A. & Mayer, D. In: Pediatric Ophthalmology and Strabismus 4th edn Ch. 4 https://doi.org/10.1016/B978-0-7020-4691-9.00004-2 (2013).
Bialer, O. Y., Goldenberg-Cohen, N., Toledano, H., Snir, M. & Michowiz, S. Retinal NFL thinning on OCT correlates with visual field loss in pediatric craniopharyngioma. Can. J. Ophthalmol. 48, 494–499 (2013).
pubmed: 24314410
doi: 10.1016/j.jcjo.2013.05.001
Rufai, S. R. Handheld optical coherence tomography removes barriers to imaging the eyes of young children. Eye 25, 127–143 (2022).
Wenzel, D., Brandl, U., Beck, J. D., Cedzich, C. & Albert, F. Visual evoked potentials in tumors from orbita to occipital lobe in childhood. Neurosurg. Rev. 11, 279–286 (1988).
pubmed: 3251171
doi: 10.1007/BF01741423
Repka, M. X., Miller, N. R. & Miller, M. Visual outcome after surgical removal of craniopharyngiomas. Ophthalmology 96, 195–199 (1989).
pubmed: 2704538
doi: 10.1016/S0161-6420(89)32914-9
Stark, K. L., Kaufman, B., Lee, B. C., Primack, J. & Tychsen, L. Visual recovery after a year of craniopharyngioma-related amaurosis: report of a nine-year-old child and a review of pathophysiologic mechanisms. J. AAPOS 3, 366–371 (1999).
pubmed: 10613582
doi: 10.1016/S1091-8531(99)70047-9
Abrams, L. S. & Repka, M. X. Visual outcome of craniopharyngioma in children. J. Pediatr. Ophthalmol. Strabismus 34, 223–228 (1997).
pubmed: 9253736
doi: 10.3928/0191-3913-19970701-09
Fisher, P. G. et al. Outcomes and failure patterns in childhood craniopharyngiomas. Childs Nerv. Syst. 14, 558–563 (1998).
pubmed: 9840379
doi: 10.1007/s003810050272
Chanson, P. et al. Management of clinically non-functioning pituitary adenoma. Ann. Endocrinol. 76, 239–247 (2015).
doi: 10.1016/j.ando.2015.04.002
Lopes, M. B. et al. in Central Nervous System Tumours in WHO Classification of Tumours Series 5th edn, Vol. 6 (ed Daniel, J. B.) Ch. 12, 406–414 (International Agency for Research on Cancer, 2021).
Lloyd, R. V., Osamura, R. Y., Kloppel, G. & Rosai, J. WHO Classification of Tumours of Endocrine Organs 4th edn (International Agency for Research on Cancer, 2017).
Neou, M. et al. Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 37, 123–134 e125 (2020).
pubmed: 31883967
doi: 10.1016/j.ccell.2019.11.002
Trouillas, J. et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 126, 123–135 (2013).
pubmed: 23400299
doi: 10.1007/s00401-013-1084-y
Chen, J., Schmidt, R. E. & Dahiya, S. Pituitary adenoma in pediatric and adolescent populations. J. Neuropathol. Exp. Neurol. 78, 626–632 (2019).
pubmed: 31115468
pmcid: 6581558
doi: 10.1093/jnen/nlz040
Villa, C. et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch. 475, 687–692 (2019).
pubmed: 31578606
doi: 10.1007/s00428-019-02655-0
Raverot, G. et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178, G1–G24 (2018).
pubmed: 29046323
doi: 10.1530/EJE-17-0796
Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469–474 (2018).
pubmed: 29539639
pmcid: 6093218
doi: 10.1038/nature26000
Vierimaa, O. et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312, 1228–1230 (2006).
pubmed: 16728643
doi: 10.1126/science.1126100
Trivellin, G. et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N. Engl. J. Med. 371, 2363–2374 (2014).
pubmed: 25470569
pmcid: 4291174
doi: 10.1056/NEJMoa1408028
Guaraldi, F., Storr, H. L., Ghizzoni, L., Ghigo, E. & Savage, M. O. Paediatric pituitary adenomas: a decade of change. Horm. Res. Paediatr. 81, 145–155 (2014).
pubmed: 24525527
doi: 10.1159/000357673
Hannah-Shmouni, F., Trivellin, G. & Stratakis, C. A. Genetics of gigantism and acromegaly. Growth Horm. IGF Res. 30-31, 37–41 (2016).
pubmed: 27657986
pmcid: 5154831
doi: 10.1016/j.ghir.2016.08.002
Denes, J. & Korbonits, M. The clinical aspects of pituitary tumour genetics. Endocrine 71, 663–674 (2021).
pubmed: 33543431
pmcid: 8016799
doi: 10.1007/s12020-021-02633-0
Daly, A. F. et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J. Clin. Endocrinol. Metab. 95, E373–E383 (2010).
pubmed: 20685857
doi: 10.1210/jc.2009-2556
Goudet, P. et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’etude des Tumeurs Endocrines. J. Clin. Endocrinol. Metab. 100, 1568–1577 (2015).
pubmed: 25594862
doi: 10.1210/jc.2014-3659
Marques, P. et al. Significant benefits of AIP testing and clinical screening in familial isolated and young-onset pituitary tumors. J. Clin. Endocrinol. Metab. 105, e2247–2260 (2020).
pubmed: 31996917
pmcid: 7137887
doi: 10.1210/clinem/dgaa040
Salenave, S., Boyce, A. M., Collins, M. T. & Chanson, P. Acromegaly and McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 99, 1955–1969 (2014).
pubmed: 24517150
pmcid: 4037730
doi: 10.1210/jc.2013-3826
Rodd, C. et al. Somatic GPR101 duplication causing X-Linked acrogigantism (XLAG)-diagnosis and management. J. Clin. Endocrinol. Metab. 101, 1927–1930 (2016).
pubmed: 26982009
pmcid: 4870851
doi: 10.1210/jc.2015-4366
Korbonits, M., Storr, H. & Kumar, A. V. Familial pituitary adenomas — who should be tested for AIP mutations? Clin. Endocrinol. 77, 351–356 (2012).
doi: 10.1111/j.1365-2265.2012.04445.x
Thakker, R. V. et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990–3011 (2012).
pubmed: 22723327
doi: 10.1210/jc.2012-1230
Rostomyan, L. et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr. Relat. Cancer 22, 745–757 (2015).
pubmed: 26187128
pmcid: 6533620
doi: 10.1530/ERC-15-0320
Iacovazzo, D. et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol. Commun. 4, 56 (2016).
pubmed: 27245663
pmcid: 4888203
doi: 10.1186/s40478-016-0328-1
Franke, M. et al. Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism. Am. J. Hum. Genet. 109, 553–570 (2022).
pubmed: 35202564
pmcid: 9069129
doi: 10.1016/j.ajhg.2022.02.002
Johnson, M. C. et al. Gps mutations in Chilean patients harboring growth hormone-secreting pituitary tumors. J. Pediatr. Endocrinol. Metab. 12, 381–387 (1999).
pubmed: 10821217
doi: 10.1515/JPEM.1999.12.3.381
Hernandez-Ramirez, L. C. et al. Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers. J. Clin. Endocrinol. Metab. 100, E1242–E1254 (2015).
pubmed: 26186299
pmcid: 4570169
doi: 10.1210/jc.2015-1869
Watanabe, D. et al. GH/PRL-secreting pituitary macroadenoma associated with GNAS p.Gln227Leu mutation: pediatric case report and review. Endocr. J. 66, 403–408 (2019).
pubmed: 30814395
doi: 10.1507/endocrj.EJ18-0370
Cuny, T. et al. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don’t forget MEN1 genetic analysis. Eur. J. Endocrinol. 168, 533–541 (2013).
pubmed: 23321498
doi: 10.1530/EJE-12-0763
Salenave, S. et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J. Clin. Endocrinol. Metab. 100, 1177–1186 (2015).
pubmed: 25532043
doi: 10.1210/jc.2014-3670
Seabrook, A. J. et al. Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5? J. Clin. Endocrinol. Metab. 106, 1163–1182 (2021).
pubmed: 33367756
doi: 10.1210/clinem/dgaa957
Kobayashi, T., Usui, H., Tanaka, H. & Shozu, M. Variant prolactin receptor in agalactia and hyperprolactinemia. N. Engl. J. Med. 379, 2230–2236 (2018).
pubmed: 30575453
doi: 10.1056/NEJMoa1805171
Newey, P. J. et al. Mutant prolactin receptor and familial hyperprolactinemia. N. Engl. J. Med. 369, 2012–2020 (2013).
pubmed: 24195502
pmcid: 4209110
doi: 10.1056/NEJMoa1307557
Chasseloup, F. et al. Germline CDKN1B loss-of-function variants cause pediatric Cushing’s disease with or without an MEN4 phenotype. J. Clin. Endocrinol. Metab. 105, 1983–2005 (2020).
pubmed: 32232325
pmcid: 7190031
doi: 10.1210/clinem/dgaa160
Rix, M. et al. Cushing’s disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur. J. Endocrinol. 151, 709–715 (2004).
pubmed: 15588237
doi: 10.1530/eje.0.1510709
Stratakis, C. A. et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 85, 4776–4780 (2000).
pubmed: 11134142
Hernandez-Ramirez, L. C. et al. Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing’s disease. Endocr. Relat. Cancer 24, 379–392 (2017).
pubmed: 28533356
pmcid: 5510591
doi: 10.1530/ERC-17-0131
de Kock, L. et al. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol. 128, 111–122 (2014).
pubmed: 24839956
pmcid: 4129448
doi: 10.1007/s00401-014-1285-z
Liu, A. P. Y. et al. Clinical outcomes and complications of pituitary blastoma. J. Clin. Endocrinol. Metab. 106, 351–363 (2021).
pubmed: 33236116
doi: 10.1210/clinem/dgaa857
Chhuon, Y. et al. Pituitary blastoma in a 19-year-old woman: a case report and review of literature. World Neurosurg. 139, 310–313 (2020).
pubmed: 32339726
doi: 10.1016/j.wneu.2020.04.096
Chong, A. S. et al. DICER1 syndrome in a young adult with pituitary blastoma. Acta Neuropathol. 32, 969–977 (2021).
Faucz, F. R. et al. Somatic USP8 gene mutations are a common cause of pediatric Cushing disease. J. Clin. Endocrinol. Metab. 102, 2836–2843 (2017).
pubmed: 28505279
pmcid: 5546857
doi: 10.1210/jc.2017-00161
Reincke, M. et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat. Genet. 47, 31–38 (2015).
pubmed: 25485838
doi: 10.1038/ng.3166
Perez-Rivas, L. G. et al. The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing cushing’s disease. J. Clin. Endocrinol. Metab. 100, E997–1004, (2015).
pubmed: 25942478
pmcid: 4490309
doi: 10.1210/jc.2015-1453
Ma, Z. Y. et al. Recurrent gain-of-function USP8 mutations in Cushing’s disease. Cell Res. 25, 306–317 (2015).
pubmed: 25675982
pmcid: 4349249
doi: 10.1038/cr.2015.20
Cohen, M. et al. Germline USP8 mutation associated with pediatric Cushing disease and other clinical features: a new syndrome. J. Clin. Endocrinol. Metab. 104, 4676–4682 (2019).
pubmed: 31162547
pmcid: 6736211
doi: 10.1210/jc.2019-00697
Tatsi, C. et al. Large genomic aberrations in corticotropinomas are associated with greater aggressiveness. J. Clin. Endocrinol. Metab. 104, 1792–1801 (2019).
pubmed: 30597087
doi: 10.1210/jc.2018-02164
Teng, X. et al. A patient with a thyrotropin-secreting microadenoma and resistance to thyroid hormone (P453T). J. Clin. Endocrinol. Metab. 100, 2511–2514 (2015).
pubmed: 25867808
pmcid: 5393528
doi: 10.1210/jc.2014-3994
Wass, J. A. H. & Lansdown, M. Endocrinology, Getting It Right First Time (GIRFT) Programme National Specialty Report https://www.gettingitrightfirsttime.co.uk/wp-content/uploads/2021/08/EndocrinologyReport-Aug21o-NEW.pdf (2021).
Casanueva, F. F. et al. Correction to: criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement. Pituitary 21, 663 (2018).
pubmed: 30238283
pmcid: 6828177
doi: 10.1007/s11102-018-0912-4
Honegger, J. & Grimm, F. The experience with transsphenoidal surgery and its importance to outcomes. Pituitary 21, 545–555 (2018).
pubmed: 30062664
doi: 10.1007/s11102-018-0904-4
Pandey, P., Ojha, B. K. & Mahapatra, A. K. Pediatric pituitary adenoma: a series of 42 patients. J. Clin. Neurosci. 12, 124–127 (2005).
pubmed: 15749410
doi: 10.1016/j.jocn.2004.10.003
Kanter, A. S. et al. Single-center experience with pediatric Cushing’s disease. J. Neurosurg. 103, 413–420 (2005).
pubmed: 16302612
Joshi, S. M. et al. Cushing’s disease in children and adolescents: 20 years of experience in a single neurosurgical center. Neurosurgery 57, 281–285 (2005).
pubmed: 16094156
doi: 10.1227/01.NEU.0000166580.94215.53
Gkourogianni, A. et al. Death in pediatric Cushing syndrome is uncommon but still occurs. Eur. J. Pediatr. 174, 501–507 (2015).
pubmed: 25241829
doi: 10.1007/s00431-014-2427-y
Dhandapani, S. et al. Endonasal endoscopic versus microscopic transsphenoidal surgery in pituitary tumors among the young: a comparative study & meta-analysis. Clin. Neurol. Neurosurg. 200, 106411 (2021).
pubmed: 33338824
doi: 10.1016/j.clineuro.2020.106411
Dyer, E. H., Civit, T., Visot, A., Delalande, O. & Derome, P. Transsphenoidal surgery for pituitary adenomas in children. Neurosurgery 34, 207–212 (1994).
pubmed: 8177379
doi: 10.1227/00006123-199402000-00001
Saldarriaga, C. et al. Postoperative diabetes insipidus and hyponatremia in children after transsphenoidal surgery for adrenocorticotropin hormone and growth hormone secreting adenomas. J. Pediatr. 195, 169–174.e1 (2018).
pubmed: 29395172
pmcid: 5869073
doi: 10.1016/j.jpeds.2017.11.042
Koumas, C. et al. Outcomes following endoscopic endonasal resection of sellar and supresellar lesions in pediatric patients. Childs Nerv. Syst. 35, 2099–2105 (2019).
pubmed: 31214816
doi: 10.1007/s00381-019-04258-1
Lamas, C., del Pozo, C. & Villabona, C., Neuroendocrinology Group of the SEEN. Clinical guidelines for management of diabetes insipidus and syndrome of inappropriate antidiuretic hormone secretion after pituitary surgery. Endocrinol. Nutr. 61, e15–e24 (2014).
pubmed: 24588923
doi: 10.1016/j.endonu.2014.01.005
de Vries, F. et al. Postoperative diabetes insipidus: how to define and grade this complication? Pituitary 24, 284–291 (2021).
pubmed: 32990908
doi: 10.1007/s11102-020-01083-7
Rajasekaran, S. et al. UK guidelines for the management of pituitary apoplexy. Clin. Endocrinol. 74, 9–20 (2011).
doi: 10.1111/j.1365-2265.2010.03913.x
Ozcetin, M., Karaci, M., Toroslu, E. & Edebali, N. A pediatric case of pituitary macroadenoma presenting with pituitary apoplexy and cranial nerve involvement: case report. Turk. Pediatr. Ars 51, 162–165 (2016).
doi: 10.5152/TurkPediatriArs.2016.1945
Villa, C. et al. Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein (AIP) gene mutation. Endocr. Relat. Cancer 18, 347–356 (2011).
pubmed: 21450940
doi: 10.1530/ERC-11-0059
Williams, F. et al. Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation. J. Clin. Endocrinol. Metab. 99, 1122–1131 (2014).
pubmed: 24423289
doi: 10.1210/jc.2013-2868
Chao, C. C. & Lin, C. J. Pituitary apoplexy in a teenager-case report. Pediatr. Neurol. 50, 648–651 (2014).
pubmed: 24842258
doi: 10.1016/j.pediatrneurol.2014.02.004
Culpin, E. et al. Pituitary tumour apoplexy within prolactinomas in children: a more aggressive condition? Pituitary 21, 474–479 (2018).
pubmed: 30014342
pmcid: 6132972
doi: 10.1007/s11102-018-0900-8
Deopujari, C. E., Shah, N. J., Shaikh, S. T., Karmarkar, V. S. & Mohanty, C. B. Endonasal endoscopic skullbase surgery in children. Childs Nerv. Syst. 35, 2091–2098 (2019).
pubmed: 31079184
doi: 10.1007/s00381-019-04167-3
Storr, H. L. et al. Endonasal endoscopic transsphenoidal pituitary surgery: early experience and outcome in paediatric Cushing’s disease. Clin. Endocrinol. 80, 270–276 (2014).
doi: 10.1111/cen.12275
Deutschbein, T. et al. First German guideline on diagnostics and therapy of clinically non-functioning pituitary tumors. Exp. Clin. Endocrinol. Diabetes 129, 250–264 (2021).
pubmed: 33690872
doi: 10.1055/a-1373-4087
Chivukula, S. et al. Endoscopic endonasal skull base surgery in the pediatric population. J. Neurosurg. Pediatr. 11, 227–241 (2013).
pubmed: 23240846
doi: 10.3171/2012.10.PEDS12160
Massimi, L. et al. Quality of postoperative course in children: endoscopic endonasal surgery versus sublabial microsurgery. Acta Neurochir. 153, 843–849 (2011).
pubmed: 21210160
doi: 10.1007/s00701-010-0929-6
Kinoshita, Y. et al. Post-operative hyponatremia in patients with pituitary adenoma: post-operative management with a uniform treatment protocol. Endocr. J. 58, 373–379 (2011).
pubmed: 21467692
doi: 10.1507/endocrj.K10E-352
Grigsby, P. W., Thomas, P. R., Simpson, J. R. & Fineberg, B. B. Long-term results of radiotherapy in the treatment of pituitary adenomas in children and adolescents. Am. J. Clin. Oncol. 11, 607–611 (1988).
pubmed: 3189225
doi: 10.1097/00000421-198812000-00001
Partington, M. D., Davis, D. H., Laws, E. R. Jr. & Scheithauer, B. W. Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J. Neurosurg. 80, 209–216 (1994).
pubmed: 8283258
doi: 10.3171/jns.1994.80.2.0209
De Menis, E. et al. Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. J. Endocrinol. Invest. 24, 92–97 (2001).
pubmed: 11263478
doi: 10.1007/BF03343820
Mehrazin, M. Pituitary tumors in children: clinical analysis of 21 cases. Childs Nerv. Syst. 23, 391–398 (2007).
pubmed: 17143643
doi: 10.1007/s00381-006-0259-4
van den Bergh, A. C. et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int. J. Radiat. Oncol. Biol. Phys. 67, 863–869 (2007).
pubmed: 17197121
doi: 10.1016/j.ijrobp.2006.09.049
Chang, E. F. et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J. Neurosurg. 108, 736–745 (2008).
pubmed: 18377253
doi: 10.3171/JNS/2008/108/4/0736
Jennings, A. S., Liddle, G. W. & Orth, D. N. Results of treating childhood Cushing’s disease with pituitary irradiation. N. Engl. J. Med. 297, 957–962 (1977).
pubmed: 909542
doi: 10.1056/NEJM197711032971801
Yordanova, G. et al. Long-term outcomes of children treated for Cushing’s disease: a single center experience. Pituitary 19, 612–624 (2016).
pubmed: 27678103
pmcid: 5080319
doi: 10.1007/s11102-016-0756-8
Fraioli, M. F., Novegno, F., Catena, E., Fraioli, C. & Moschettoni, L. Multidisciplinary treatment of giant invasive prolactinomas in paediatric age: long-term follow-up in two children. Childs Nerv. Syst. 26, 1233–1237 (2010).
pubmed: 20352234
doi: 10.1007/s00381-010-1129-7
Shrivastava, A. et al. Outcomes after gamma knife stereotactic radiosurgery in pediatric patients with Cushing disease or acromegaly: a multi-institutional study. World Neurosurg. 125, e1104–e1113 (2019).
pubmed: 30790739
doi: 10.1016/j.wneu.2019.01.252
Pomeraniec, I. J., Dallapiazza, R. F., Xu, Z., Jane, J. A. Jr. & Sheehan, J. P. Early versus late Gamma Knife radiosurgery following transsphenoidal resection for nonfunctioning pituitary macroadenomas: a matched cohort study. J. Neurosurg. 125, 202–212 (2016).
pubmed: 26517773
doi: 10.3171/2015.5.JNS15581
Jalali, R. et al. Stereotactic conformal radiotherapy for pituitary adenomas: technique and preliminary experience. Clin. Endocrinol. 52, 695–702 (2000).
doi: 10.1046/j.1365-2265.2000.00967.x
Colin, P. et al. Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Int. J. Radiat. Oncol. Biol. Phys. 62, 333–341 (2005).
pubmed: 15890572
doi: 10.1016/j.ijrobp.2004.09.058
Mackley, H. B. et al. Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland Clinic experience. Int. J. Radiat. Oncol. Biol. Phys. 67, 232–239 (2007).
pubmed: 17084541
doi: 10.1016/j.ijrobp.2006.08.039
Elhateer, H. et al. Fractionated stereotactic radiotherapy in the treatment of pituitary macroadenomas. Curr. Oncol. 15, 286–292 (2008).
pubmed: 19079630
pmcid: 2601024
doi: 10.3747/co.v15i6.293
Arauz, R. & Rodriguez, M. In: 19th Annual Scientific Meeting of the Society for Neuro-Oncology (Oxford Journals, 2015).
Almeldin, D. et al. Radiotherapy for Pituitary Tumors. ENDOTEXT. https://www.ncbi.nlm.nih.gov/pubmed/25905190 (2023).
Storr, H. L. et al. Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing’s disease: an effective second-line treatment. J. Clin. Endocrinol. Metab. 88, 34–37 (2003).
pubmed: 12519825
doi: 10.1210/jc.2002-021032
Ronson, B. B. et al. Fractionated proton beam irradiation of pituitary adenomas. Int. J. Radiat. Oncol. Biol. Phys. 64, 425–434 (2006).
pubmed: 16257131
doi: 10.1016/j.ijrobp.2005.07.978
Merchant, T. E. et al. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr. Blood Cancer 51, 110–117 (2008).
pubmed: 18306274
doi: 10.1002/pbc.21530
Combs, S. E. et al. Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. Acta Oncol. 52, 1504–1509 (2013).
pubmed: 23962241
doi: 10.3109/0284186X.2013.818255
Plowman, P. N. Pituitary adenoma radiotherapy-when, who and how? Clin. Endocrinol. 51, 265–271 (1999).
doi: 10.1046/j.1365-2265.1999.00854.x
Loeffler, J. S. & Shih, H. A. Radiation therapy in the management of pituitary adenomas. J. Clin. Endocrinol. Metab. 96, 1992–2003 (2011).
pubmed: 21525155
doi: 10.1210/jc.2011-0251
Grabenbauer, G. G., Ernst-Stecken, A., Schneider, F., Lambrecht, U. & Ganslandt, O. Radiosurgery of functioning pituitary adenomas: comparison of different treatment techniques including dynamic and conformal arcs, shaped beams, and IMRT. Int. J. Radiat. Oncol. Biol. Phys. 66, S33–S39 (2006).
doi: 10.1016/j.ijrobp.2006.05.076
Sheehan, J. P. et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J. Neurosurg. 102, 678–691 (2005).
pubmed: 15871511
doi: 10.3171/jns.2005.102.4.0678
Sheehan, J. P. et al. Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J. Neurosurg. 119, 446–456 (2013).
pubmed: 23621595
doi: 10.3171/2013.3.JNS12766
Xu, Z., Lee Vance, M., Schlesinger, D. & Sheehan, J. P. Hypopituitarism after stereotactic radiosurgery for pituitary adenomas. Neurosurgery 72, 630–637 (2013).
pubmed: 23277375
doi: 10.1227/NEU.0b013e3182846e44
Mitsumori, M. et al. Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int. J. Radiat. Oncol. Biol. Phys. 42, 573–580 (1998).
pubmed: 9806517
doi: 10.1016/S0360-3016(98)00256-9
Brada, M. et al. Cerebrovascular mortality in patients with pituitary adenoma. Clin. Endocrinol. 57, 713–717 (2002).
doi: 10.1046/j.1365-2265.2002.01570.x
Sattler, M. G. et al. The incidence of second tumours and mortality in pituitary adenoma patients treated with postoperative radiotherapy versus surgery alone. Radiother. Oncol. 104, 125–130 (2012).
pubmed: 22682541
doi: 10.1016/j.radonc.2012.04.024
Minniti, G. et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin. Endocrinol. 62, 210–216 (2005).
doi: 10.1111/j.1365-2265.2005.02199.x
Burman, P., van Beek, A. P., Biller, B. M., Camacho-Hubner, C. & Mattsson, A. F. Radiotherapy, especially at young age, increases the risk for de novo brain tumors in patients treated for pituitary/sellar lesions. J. Clin. Endocrinol. Metab. 102, 1051–1058 (2017).
pubmed: 28359095
doi: 10.1210/jc.2016-3402
Swerdlow, A. J. et al. Risk of meningioma in European patients treated with growth hormone in childhood: results from the SAGhE cohort. J. Clin. Endocrinol. Metab. 104, 658–664 (2019).
pubmed: 30137467
doi: 10.1210/jc.2018-01133
Swerdlow, A. J. et al. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European Cohort Study. J. Clin. Endocrinol. Metab. 102, 1661–1672 (2017).
pubmed: 28187225
doi: 10.1210/jc.2016-2046